Verana Health announces the launch of new AI agents to accelerate life sciences R&D, led by Agent Claire for Life Sciences with disease-specific versions, marking a shift from tool-based augmentation to full AI agent integration across core operations.

Agent Claire is designed to speed development timelines and improve patient access to therapies by integrating AI agents into workflows that previously relied on manual tools.

The system emphasizes transparency and governance, delivering underlying query logic with each answer and aligning with validated queries and cautionary guidance for complex analyses.

Researchers can generate analytic insights through conversational queries on real-world data, receiving execution plans, embedded clinical guardrails, and SQL outputs for validation without programming.

Verana invites readers to learn more at veranahealth.com and visit the AAO 2026 Annual Meeting booth in New Orleans, with options to schedule meetings in advance.

Agent Claire can craft step-by-step query strategies for complex research goals, such as mapping treatment progression in diseases like multiple myeloma, with review, refinement, or execution as needed.

Claire is interoperable with leading AI agents via the Model Context Protocol, allowing users to work with their preferred AI agent while benefiting from Claire’s clinical knowledge in the background.

The AI agents are available across Verana Health real-world data datasets in oncology, ophthalmology, and urology, targeting brand managers, medical affairs, market access, and HEOR teams for rapid, evidence-backed answers on patient distributions, treatment patterns, and outcomes.

McKinsey & Company projects life sciences agents could boost clinical development productivity by 35-45% by 2030 and unlock $60-110 billion+ in annual pharma revenue, highlighting the potential impact.